Verismo Therapeutics, a clinical-stage CAR-T company and University of Pennsylvania spinout developing novel KIR-CAR platform technology, today announced that it has activated its STAR-101 Phase 1 clinical trial at the University of Pennsylvania.
| Clinical-stage CAR-T company is actively recruiting patients for Phase 1 trial to evaluate SynKIR™-110, a new treatment for pleural mesothelioma, cholangiocarcinoma and ovarian cancer PHILADELPHIA, May 2, 2023 /PRNewswire/ -- Verismo Therapeutics, a clinical-stage CAR-T company and University of Pennsylvania spinout developing novel KIR-CAR platform technology, today announced that it has activated its STAR-101 Phase 1 clinical trial at the University of Pennsylvania.
STAR-101 will evaluate Verismo’s lead candidate, SynKIR™-110, an investigational new drug for the treatment of mesothelin-overexpressing malignant pleural mesothelioma, cholangiocarcinoma and ovarian cancer. Verismo Therapeutics is conducting a Phase 1 multicenter clinical trial in these tumor types to evaluate the feasibility and safety of SynKIR-110 (ClinicalTrials.gov Identifier: NCT05568680). Verismo achieved clearance from the FDA to administer this multicenter clinical trial under the IND Verismo submitted for SynKIR™-110, and Orphan Drug Designation for the treatment of mesothelin-expressing mesotheliomas with SynKIR™-110 in September 2022. SynKIR ™-110 received Fast Track designation in April 2023. “This trial marks a pivotal moment for our company,” said Dr. Bryan Kim, Co-Founder and CEO of Verismo Therapeutics. We are grateful for the opportunity to partner with distinguished researchers at the University of Pennsylvania, including Dr. Janos Tanyi, MD, PhD, Dr. Andrew Haas, MD, PhD, and Dr. Mark O’Hara, MD, to bring this innovative therapy to those who require it the most.” Dr. Tanyi, an associate professor of Obstetrics and Gynecology in the Perelman School of Medicine at the University of Pennsylvania, and a principal investigator for the trial, said, “Our team is excited to be part of this clinical trial with Verismo. We are enthusiastic about the prospects of this innovative therapy and its capacity to provide new hope and improved outcomes for individuals who urgently need effective treatment options.” For more information about the STAR-101 clinical trial, please visit ClinicalTrials.gov NCT05568680. About the KIR-CAR Platform About Verismo Therapeutics Editor’s Note: Penn holds equity interests in Verismo and has licensed certain Penn-owned intellectual property to Verismo. Penn’s Perelman School of Medicine receives funding for research and development of certain Verismo products. Penn may receive future financial benefits related to the licensing of certain Penn intellectual property to Verismo. Media Contact:
SOURCE Verismo Therapeutics |
View original content to download multimedia:
